NEW YORK (GenomeWeb News) – Companion diagnostics and biomarker development company Flagship Biosciences announced late on Monday its purchase of immunohistochemistry and immunofluorescence firm IHCtech for an undisclosed amount.
In a statement, Flagship President David Young said the deal provides his company "the opportunity to internally evaluate tissue staining and implement new processes that better equip immunohistochemistry operations for use in quantitative pathology with whole slide imaging analysis."
Patsy Ruegg, the owner and founder of IHCtech, added that the two companies have partnered on several new techniques and approaches for quantitation in immunohistochemistry, and Flagship's approaches to whole slide analysis and commitment to quantitative pathology "makes a perfect partner with IHCtech's expertise in high quality histology and immunohistochemistry."
Flagship, based in Flagstaff, Ariz., is focused on tissue-based companion diagnostics, immunohistochemistry biomarker development, and histopathology assessment of discovery, safety, and toxicity using brightfield and fluorescent whole slide imaging. IHCtech is headquartered at the Colorado Anschutz Medical Campus and provides histology, immunohistochemistry, and immunofluorescence services to the academic and pharmaceutical end markets.